Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus ONMEL.
FLURBIPROFEN SODIUM vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
50 mg orally twice daily for 14 days
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID